Publicaciones en colaboración con investigadores/as de Hospital Arnau de Vilanova (40)

2014

  1. Iron deficiency in patients with solid tumours: Prevalence and management in clinical practice

    Clinical and Translational Oncology, Vol. 16, Núm. 9, pp. 823-828

2013

  1. Tratamiento del cáncer de tiroides

    Revisiones en Cancer, Vol. 27, Núm. 2, pp. 70-85

2012

  1. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 30, Núm. 25, pp. 3084-3092

  2. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum

    Lung Cancer, Vol. 76, Núm. 3, pp. 354-361

2011

  1. Experiencia con sunitinib en cáncer de próstata metastásico hormonorresistente sin respuesta a docetaxel

    Actas Urologicas Espanolas, Vol. 35, Núm. 1, pp. 57-60

  2. Melanoma from darkness to promise

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 34, Núm. 2, pp. 179-187

  3. Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 34, Núm. 2, pp. 155-159

2010

  1. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients

    Lung Cancer, Vol. 68, Núm. 3, pp. 491-497

  2. Experience with fulvestrant acetate in castration-resistant prostate cancer patients

    Annals of Oncology

  3. Old and new insights in the treatment of thyroid carcinoma

    Journal of Thyroid Research, Vol. 2010

2009

  1. Considering SRC-ABL as a promising therapeutic target in cancer

    Cancer Therapy, Vol. 7, Núm. ISSUE A, pp. 200-214

  2. Fulvestrant activity in the treatment of metastatic prostate cancer

    Cancer Therapy, Vol. 7, Núm. ISSUE A, pp. 215-218

  3. PET and PET-CT in the staging and treatment of non-small cell lung cancer

    Cancer Therapy, Vol. 7, Núm. ISSUE A, pp. 309-319

  4. Predictors of long-term survival in patients with lung cancer included in the Randomized Spanish Lung Cancer Group 0008 Phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy

    Clinical Lung Cancer, Vol. 10, Núm. 3, pp. 180-186

  5. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

    Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 727-736

  6. Treatment of small-cell lung cancer

    Cancer and Chemotherapy Reviews, Vol. 4, Núm. 3, pp. 131-140

  7. Treatment options for metastatic melanoma. A systematic review

    Cancer Therapy, Vol. 7, Núm. ISSUE A, pp. 188-199

2008

  1. Anemia asociada al cáncer de pulmón: ¿factor pronóstico, predictivo, ambos o ninguno?

    Medicina Clinica

  2. Atrial flutter and myocardial infarction-like ECG changes as manifestations of left ventricle involvement from lung carcinoma

    Clinical and Translational Oncology, Vol. 10, Núm. 2, pp. 125-127

  3. Screening and chemoprevention in lung cancer

    Clinical and Translational Oncology, Vol. 10, Núm. 5, pp. 274-280